They showed that this conjugated peptidomimetic could have antiproliferative activity in lung cancer cell A549, and other cell types like Calu-3 and BT-474 that overexpressed HER2 by binding specifically to the HER2 extracellular domain, particularly to domain IV, and inhibits human epidermal growth factor receptor (EGFR) heterodimerization. Here, ERBB2 is linked to lung carcinoma.